Syros Pharmaceuticals Inc (NAS:SYRS)
$ 0.2159 0.013 (6.41%) Market Cap: 5.79 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 25/100

Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed Unfit AML-Call Transcript

Jun 22, 2021 / 12:30PM GMT
Release Date Price: $52.1 (+2.16%)
Operator

Good morning, ladies and gentlemen, and welcome to the SY-1425 for newly diagnosed and unfit acute myeloid leukemia conference call.

(Operator Instructions)

As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Nancy Simonian, Chief Executive Officer of Syros Pharmaceuticals. Please, go ahead.

Nancy A. Simonian
Syros Pharmaceuticals, Inc. - President, CEO, Interim Principal Financial & Accounting Officer and Director

Great. Thank you, operator. Good morning, and welcome to our KOL event on SY-1425 in newly diagnosed unfit AML.

We will be making forward-looking statements. A full description of our risk factors can be found on our website. This is the second of a 3-part series of KOL events on our targeted hematology portfolio.

We are very pleased to have Dr. Daniel Pollyea, the Associate Professor of Medicine, Clinical Director of the Leukemia Services and the Robert H. Allen Chair in Hematology Research at the University of Colorado School of Medicine as our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot